1437 related articles for article (PubMed ID: 26408274)
1. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
3. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
4. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.
Chu AY; Giulianini F; Barratt BJ; Ding B; Nyberg F; Mora S; Ridker PM; Chasman DI
Circ Cardiovasc Genet; 2015 Oct; 8(5):688-95. PubMed ID: 26273092
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
6. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Mora S; Glynn RJ; Ridker PM
Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
[TBL] [Abstract][Full Text] [Related]
8. Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.
Ajala ON; Demler OV; Liu Y; Farukhi Z; Adelman SJ; Collins HL; Ridker PM; Rader DJ; Glynn RJ; Mora S
J Am Heart Assoc; 2020 Sep; 9(17):e016507. PubMed ID: 32799709
[TBL] [Abstract][Full Text] [Related]
9. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
10. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
11. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Khera AV; Everett BM; Caulfield MP; Hantash FM; Wohlgemuth J; Ridker PM; Mora S
Circulation; 2014 Feb; 129(6):635-42. PubMed ID: 24243886
[TBL] [Abstract][Full Text] [Related]
13. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
[TBL] [Abstract][Full Text] [Related]
14. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
[TBL] [Abstract][Full Text] [Related]
15. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
16. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
18. Group IIA Secretory Phospholipase A
Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
[TBL] [Abstract][Full Text] [Related]
19. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
Nishikido T; Oyama J; Keida T; Ohira H; Node K
J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
[TBL] [Abstract][Full Text] [Related]
20. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
